Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

Navarese, Eliano Pio; Podhajski, Przemysław; Andreotti, Felicita; Torre, Giuseppe La; Gajda, Robert; Radziwanowski, Adrian; Nowicka, Małgorzata; Bukowski, Pawel; Gajda, Jacek; Omyła, Maciej; Lackowski, Piotr; Piasecki, Maciej; Jasiewicz, Małgorzata; Szymański, Paweł; Pietrzykowski, Łukasz; Michalski, Piotr; Kubica, Aldona; Urbanowicz, Iwona; Orsini, Nicola; Conte, Max; Pinkas, Jarosław; Brouwer, Marc A.; Kubica, Jacek

doi:10.5603/cj.a2022.0072

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies investigating CCB associations with similar outcomes have found mild benefits [20,21,33,34]; however, these were all associated with limitations such as a small sample size (i.e., less than 25) or a lack of adjustment for race as a confounder. A recently concluded multicenter, international clinical trial, the Recovery-SIRIO (NCT04351763) study, found that neither amiodarone nor verapamil significantly accelerated short-term clinical improvement [35], which is in agreement with our data.…”

Section: Discussionsupporting

confidence: 92%

The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

Kim

Nadarajan

Ahmed

et al. 2023

COVID

View full text Add to dashboard Cite

(1) Background: Data on COVID-19 outcomes and disease course as a function of different medications used to treat cardiovascular disease and chronic kidney disease (CKD), as well as the presence of different comorbidities in primarily Black cohorts, are lacking. (2) Methods: We conducted a retrospective medical chart review on 327 patients (62.6% Black race) who were admitted to the Detroit Medical Center, Detroit, MI. Group differences (CKD vs. non-CKD) were compared using the Pearson χ2 test. We conducted univariate and multivariate regression analyses for factors contributing to death during hospitalization due to COVID-19 (primary outcome) and ICU admission (secondary outcome), adjusting for age, sex, different medications, and comorbidities. A sub-analysis was also completed for CKD patients. (3) Results: In the fully adjusted model, a protective effect of ACEi alone, but not in combination with ARB or CCB, for ICU admission was found (OR = 0.400, 95% CI [0.183–0.874]). Heart failure was significantly associated with the primary outcome (OR = 4.088, 95% CI [1.1661–14.387]), as was COPD (OR = 3.747, 95% CI [1.591–8.828]). (4) Conclusions: Therapeutic strategies for cardiovascular disease and CKD in the milieu of different comorbidities may need to be tailored more prudently for individuals with COVID-19, especially Black individuals.

show abstract

Section: Discussionsupporting

confidence: 92%

The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

Kim

Nadarajan

Ahmed

et al. 2023

COVID

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the trial with Umifenovir revealed that it was ineffective in shortening the duration of SARS-CoV-2 in severe patients and did not improve the prognosis in non-ICU patients and mortality ( Darazam, 2021 ). Neither Amiodarone nor Verapamil too, were found to significantly accelerate short-term clinical improvement in hospitalised COVID-19 patients ( Navarese et al, 2022 ). Although overall results reported for Nafamostat were not highly encouraging, one group observed a shorter median time to clinical improvement in a small group of high-risk COVID-19 patients requiring oxygen treatment ( Zhuravel, 2021 ; NCT04623021).…”

Section: Sars-cov-2 Entry Inhibitors In Clinical and Preclinical Testingmentioning

confidence: 97%

Targeting SARS-CoV-2 and host cell receptor interactions

Lim

2023

Antiviral Research

View full text Add to dashboard Cite

“…Tummino et al [3] established that the threshold concentration for inducing phospholipidosis in cultured cells is correlated to the antiviral activity. Several drugs from the list, including chloroquine, hydroxycholoquine and amiodarone, have been investigated in clinical trials for COVID-19 treatment or prevention, but without success [2,3,[7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention

Marceau

2022

DDC

View full text Add to dashboard Cite

The hope for the rapid discovery of an effective drug therapy for COVID-19 has led to several efforts to repurpose drugs approved for other indications. Lysosomotropic drugs, organic amines such as chloroquine, hydroxychloroquine, amiodarone and many others, were found to interfere with the viral life cycle in vitro but have failed in clinical trials. The properties of lysosomotropic drugs and the vacuolar cytopathology induced by them are briefly reviewed, including the critical role of lipophilicity, the central role of vacuolar (V)-ATPase for their concentration in acidic organelles, the altered function of these organelles including impaired endocytosis and secretion, macroautophagic accumulation and secondary phospholipidosis. The apparent preferential uptake of lysosomotropic drugs by phagocytic leukocytes (macrophages, neutrophils) and the high concentrations needed for a sustained disruption of vacuolar trafficking may have contributed to the failure of lysosomotropic drug repurposing for COVID-19.

show abstract

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.

Cited by 4 publications

References 22 publications

The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

Targeting SARS-CoV-2 and host cell receptor interactions

Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention

Contact Info

Product

Resources

About